新型糖肽类抗生素LY333328对多重耐药革兰氏阳性临床分离株的体外活性
In vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolates.
作者信息
García-Garrote F, Cercenado E, Alcalá L, Bouza E
机构信息
Servicio de Microbiología, Hospital General Universitario "Gregorio Marañón," Madrid, Spain.
出版信息
Antimicrob Agents Chemother. 1998 Sep;42(9):2452-5. doi: 10.1128/AAC.42.9.2452.
Abstract
The in vitro activity of LY333328 was compared with those of vancomycin and teicoplanin against 425 gram-positive clinical isolates, including a variety of multiply resistant strains. LY333328 at </=4 microgram/ml inhibited all microorganisms tested, including methicillin- and teicoplanin-resistant staphylococci, glycopeptide-resistant enterococci, penicillin- and multiply resistant pneumococci, and viridans and beta-hemolytic streptococci.
摘要
将LY333328的体外活性与万古霉素和替考拉宁针对425株革兰氏阳性临床分离菌（包括多种多重耐药菌株）的活性进行了比较。浓度≤4微克/毫升的LY333328抑制了所有测试的微生物，包括耐甲氧西林和耐替考拉宁的葡萄球菌、耐糖肽的肠球菌、耐青霉素和多重耐药的肺炎球菌以及草绿色链球菌和β-溶血性链球菌。
相似文献
1
In vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolates.新型糖肽类抗生素LY333328对多重耐药革兰氏阳性临床分离株的体外活性
Antimicrob Agents Chemother. 1998 Sep;42(9):2452-5. doi: 10.1128/AAC.42.9.2452.
2
In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.新型半合成糖肽LY333328的体外抗菌活性
Antimicrob Agents Chemother. 1997 Oct;41(10):2165-72. doi: 10.1128/AAC.41.10.2165.
3
Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin.与万古霉素和替考拉宁相比，糖肽类抗生素LY333328的体外活性评估。
J Antimicrob Chemother. 1998 Feb;41(2):273-6. doi: 10.1093/jac/41.2.273.
4
Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant gram-positive organisms.一种新型糖肽类抗生素（LY333328）对肠球菌及其他耐药革兰氏阳性菌的活性。
J Antimicrob Chemother. 1997 Sep;40(3):423-5. doi: 10.1093/jac/40.3.423.
5
In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates.利奈唑胺对多重耐药革兰氏阳性临床分离株的体外活性。
J Antimicrob Chemother. 2001 Jan;47(1):77-81. doi: 10.1093/jac/47.1.77.
6
In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae.LY333328对耐万古霉素肠球菌、耐甲氧西林金黄色葡萄球菌和耐青霉素肺炎链球菌的体外活性。
Diagn Microbiol Infect Dis. 1998 Feb;30(2):89-92. doi: 10.1016/s0732-8893(97)00207-1.
7
In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study.LY333328及对照药物对1997年全球监测研究中收集的医院革兰氏阳性病原菌的体外活性。
Antimicrob Agents Chemother. 2000 May;44(5):1370-4. doi: 10.1128/AAC.44.5.1370-1374.2000.
8
In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci.研究性糖肽类抗生素LY333328对肠球菌和葡萄球菌的体外活性。
Antimicrob Agents Chemother. 1996 Oct;40(10):2416-9. doi: 10.1128/AAC.40.10.2416.
9
The in-vitro activity of LY333328, a new glycopeptide, against clinical isolates of vancomycin-resistant enterococci.新型糖肽类药物LY333328对耐万古霉素肠球菌临床分离株的体外活性
Adv Exp Med Biol. 1997;418:483-5. doi: 10.1007/978-1-4899-1825-3_115.
10
[Antimicrobial spectrum of dalbavancin. Mechanism of action and in vitro activity against Gram-positive microorganisms].[达巴万星的抗菌谱。作用机制及对革兰氏阳性微生物的体外活性]
Enferm Infecc Microbiol Clin. 2017 Jan;35 Suppl 1:9-14. doi: 10.1016/S0213-005X(17)30029-0.
引用本文的文献
1
Endocarditis Caused by Highly Penicillin-Resistant Viridans Group Streptococci: Still Room for Vancomycin-Based Regimens.由高度耐青霉素的草绿色链球菌引起的心内膜炎：万古霉素为基础的治疗方案仍有一席之地。
Antimicrob Agents Chemother. 2019 Jul 25;63(8). doi: 10.1128/AAC.00516-19. Print 2019 Aug.
2
Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.特拉万星：一种新型半合成脂糖肽类药物，用于应对耐革兰氏阳性病原体的挑战。
Ther Adv Infect Dis. 2017 Mar;4(2):49-73. doi: 10.1177/2049936117690501. Epub 2017 Mar 8.
3
Oritavancin diphosphate.奥利万星二磷酸盐
Hosp Pharm. 2014 Dec;49(11):1049-60. doi: 10.1310/hpj4911-1049.
4
Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.聚山梨醇酯80对奥利万星与塑料表面结合的影响：对药敏试验的意义。
Antimicrob Agents Chemother. 2008 May;52(5):1597-603. doi: 10.1128/AAC.01513-07. Epub 2008 Feb 25.
5
New drugs to treat skin and soft tissue infections.治疗皮肤和软组织感染的新药。
Curr Infect Dis Rep. 2007 Sep;9(5):408-14. doi: 10.1007/s11908-007-0063-7.
6
Glycopeptide antibiotics: from conventional molecules to new derivatives.糖肽类抗生素：从传统分子到新衍生物
Drugs. 2004;64(9):913-36. doi: 10.2165/00003495-200464090-00001.
7
Comparative in vitro activities of AC98-6446, a novel semisynthetic glycopeptide derivative of the natural product mannopeptimycin alpha, and other antimicrobial agents against gram-positive clinical isolates.新型半合成糖肽衍生物AC98 - 6446（天然产物甘露肽霉素α的衍生物）与其他抗菌药物对革兰氏阳性临床分离株的体外比较活性。
Antimicrob Agents Chemother. 2004 Mar;48(3):739-46. doi: 10.1128/AAC.48.3.739-746.2004.
8
Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis.LY333328（奥利万星）单独及联合应用治疗耐头孢菌素肺炎球菌性脑膜炎的实验研究
Antimicrob Agents Chemother. 2003 Jun;47(6):1907-11. doi: 10.1128/AAC.47.6.1907-1911.2003.
9
In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens.替加环素（GAR-936）、达托霉素及其他对照抗菌药物对糖肽类中介金黄色葡萄球菌及其他耐药革兰氏阳性病原体的体外和体内活性。
Antimicrob Agents Chemother. 2002 Aug;46(8):2595-601. doi: 10.1128/AAC.46.8.2595-2601.2002.
10
Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin.LY333328对一株对青霉素敏感的肺炎链球菌引起的实验性脑膜炎的活性。
Antimicrob Agents Chemother. 2001 Jul;45(7):2169-72. doi: 10.1128/AAC.45.7.2169-2172.2001.
本文引用的文献
1
In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.新型半合成糖肽LY333328的体外抗菌活性
Antimicrob Agents Chemother. 1997 Oct;41(10):2165-72. doi: 10.1128/AAC.41.10.2165.
2
Time-kill curves for a semisynthetic glycopeptide, LY333328, against vancomycin-susceptible and vancomycin-resistant Enterococcus faecium strains.半合成糖肽类药物LY333328对万古霉素敏感和耐药的屎肠球菌菌株的时间杀菌曲线。
Antimicrob Agents Chemother. 1997 Jun;41(6):1407-8. doi: 10.1128/AAC.41.6.1407.
3
Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium.新型糖肽类药物LY333328的药效学评价及其对金黄色葡萄球菌和粪肠球菌的体外活性
Antimicrob Agents Chemother. 1997 Jun;41(6):1307-12. doi: 10.1128/AAC.41.6.1307.
4
In vitro activity and spectrum of LY333328, a novel glycopeptide derivative.新型糖肽衍生物LY333328的体外活性及抗菌谱
Antimicrob Agents Chemother. 1997 Feb;41(2):488-93. doi: 10.1128/AAC.41.2.488.
5
Comparative activities of LY 333328, a new glycopeptide, against penicillin-susceptible and -resistant pneumococci.新型糖肽类药物LY 333328对青霉素敏感及耐药肺炎球菌的比较活性
Antimicrob Agents Chemother. 1996 Nov;40(11):2661-3. doi: 10.1128/AAC.40.11.2661.
6
In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci.研究性糖肽类抗生素LY333328对肠球菌和葡萄球菌的体外活性。
Antimicrob Agents Chemother. 1996 Oct;40(10):2416-9. doi: 10.1128/AAC.40.10.2416.
7
Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci.源自LY264826的半合成糖肽类抗生素，对耐万古霉素肠球菌具有活性。
Antimicrob Agents Chemother. 1996 Sep;40(9):2194-9. doi: 10.1128/AAC.40.9.2194.
8
Nosocomial enterococci resistant to vancomycin--United States, 1989-1993.1989 - 1993年美国医院内耐万古霉素肠球菌
MMWR Morb Mortal Wkly Rep. 1993 Aug 6;42(30):597-9.
9
Methicillin-resistant staphylococci: detection methods and treatment of infections.耐甲氧西林葡萄球菌：检测方法与感染治疗
Antimicrob Agents Chemother. 1989 Jul;33(7):995-9. doi: 10.1128/AAC.33.7.995.
10
Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System.1980 - 1989年美国医院原发性血流感染的长期趋势。国家医院感染监测系统。
Am J Med. 1991 Sep 16;91(3B):86S-89S. doi: 10.1016/0002-9343(91)90349-3.
Zotero 插件